Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific AssemblyGlobeNewsWire • 06/30/23
Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common StockGlobeNewsWire • 05/24/23
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial ResultsGlobeNewsWire • 04/28/23
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated RetinopathiesGlobeNewsWire • 04/27/23
Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor ConferenceGlobeNewsWire • 04/26/23
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual MeetingGlobeNewsWire • 04/20/23
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital AmaurosisGlobeNewsWire • 04/14/23
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)GlobeNewsWire • 03/27/23